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1. Introduction 
Dehydroepiandrosterone (DHEA) (1) is the major adrenal androgen of young adults. 
However, serum concentration of DHEA in 60 year- old men shows a gradual decrease, 
when compared with young men aged 25-30 years old. This decrease occurs as the incidence 
of atherosclerosis (2), obesity (3), and diabetes increases (4), suggesting that administration 
of DHEA may protect against the development of these disorders. Previously, we reported 
that in vitro DHEA treatment increased glucose uptake and activation of PI 3-kinase in 
native rat adipocytes (5).  
Protein kinase C (PKC) is a family of serine/threonine kinases, which play key functions in 
cellular signal transduction. Three categories of PKC, conventional, novel, and atypical 
PKCs, have been described depending on their mechanisms of activation. Moreover, it is 
known that 3-phosphoinositide-dependent protein kinase-1 (PDK1) is the hub of many 
signaling pathways, which phosphorylate many downstream kinases of 
phosphatidylinositol 3-kinase (PI 3-kinase), such as Akt kinase, S6 kinase and PKC. Previous 
studies suggested that atypical PKC (aPKC/) isoforms are required for insulin stimulation 
of glucose uptake (6), and PDK1 is necessary for activation of aPKCs (7).  
It has been reported that DHEA treatment reduces fat accumulation and protects against 
insulin resistance via an increase in PI 3-kinase after immunoprecipitation with insulin 
receptor substrate-1 (IRS-1) in male rats (8). We have investigated the in-vitro and in-vivo 
effects of DHEA on insulin-induced glucose uptake in adipocytes of Otsuka Log-Evans 
Tokushima fatty (OLETF) (9) and LETO rats. Moreover, we have shown the DHEA-induced 
glucose uptake by activation of PI 3-kinase/atypaical PKC siganlling without association 
with IRS-1 (10). In vivo treatment with DHEA affects on a decrease of adipose tissue via 
downregulation of peroxisome proliferator-activated receptor  (PPAR) expression (11). 
Based on above results, we have searched more precise mechanism of DHEA-induced 
amelioration of insulin sensitivity and clinical application of DHEA in diabetic animal 
models and human male adults. 
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Obesity is one of the most important public health problems because of its association with 
increased risk for diabetes, hypertension, coronary heart disease, and other serious diseases. 
In addition to the environmental factors including a western style diet, hormonal changes 
are postulated to up- or downregulate adiposity. Recent evidence indicates that 
hypogonadism is a predictor of obesity, insulin resistance, diabetes, and coronary artery 
disease in men (12). Testosterone replacement therapy improves insulin resistance and 
glycemic control in hypogonadal men with type 2 diabetes (13). Male hypogonadism is a 
distinctly defined clinical entity associated with sexual dysfunction, inactivity, depression, 
decreased muscle mass, bone loss, etc. Hence, testosterone replacement also improves these 
abnormalities (14). On the other hand, although circulating DHEA and testosterone 
concentrations are known to decline during the aging process (15) in men, the relationship 
between low plasma DHEA level and cardiovascular disease remains controversial. Barrett-
Connor and colleagues reported negative correlation between DHEA sulfate (DHEA-S) level 
and death from any case and death from cardiovascular disease in men more than 50 years 
of age (16). The same authors concluded that DHEA-S did not predict cardiovascular death 
in women (17). Analyses of the relationship of plasma DHEA or DHEA-S levels with obesity 
or body fat distribution have revealed inconsistent results. Plasma DHEA levels are 
negatively correlated with total body mass index and abdominal fat accumulation; however, 
contradictory is true for the relationship between DHEA-S and adiposity. Several studies 
supported the association of high plasma DHEA level with favorable insulin sensitivity (18). 
Meanwhile, administration of DHEA has been reported to improve obesity (19), diabetes 
(20), and cancer (21) in animal studies. However, discrepancies have been reported in the 
benefit of DHEA administration in human studies. Both positive (22) and negative (23) 
effects of DHEA replacement in elderly people or in patients with adrenal insufficiency have 
been reported. A major cause of these discrepancies might be the varied study designs 
including the selection of subjects, dose, drug administration, and definitions of endpoint in 
these numerous studies.  
Although the specific receptor of DHEA has not been identified, one recently proposed 
mechanism is that DHEA is a precursor of androgen and estrogen that is converted to active 
form in peripheral tissues. DHEA is metabolized into androstenedione with 3ǃ-
hydroxysteroid dehydrogenase, and then transformed to testosterone with 17ǃ-
hydroxysteroid dehydrogenase (intracrine process) (24). The fact that androgen receptor 
(AR)-deficient mice are obese (25) indicates that AR acts as a mediator to prevent fat 
accumulation in whole body. Accordingly, several effects of DHEA may be mediated via 
AR. In this regard, it is possible that DHEA and testosterone have common mechanisms to 
reduce adiposity. However, few comparative studies between these hormones have been 
reported (26). 
We demonstrated that administration of DHEA reduced adiposity in Otsuka Long-Evans 
Tokushima Fatty (OLETF) rats. Moreover, we found that DHEA directly downregulated the 
PPARǄ mRNA level in cultured adipocytes, which may explain the anti-obesity effect of 
DHEA (11). However, contradictory data have been reported lately (27). To understand the 
weight-reducing effect of DHEA comprehensively, we performed a microarray study. 
Analysis of approximately 30,000 genes in epididymal fat isolated from mice after treatment 
with or without DHEA demonstrated that although a few genes involved in energy 
metabolism (e.g., malonyl-CoA decarboxylase) were affected, genes regulating cell growth 
(e.g., foxa1, nuclear factor I/X, eukaryotic translation elongation factor 1ǂ, and aurora 
kinase) and genes regulating apoptosis (e.g., caspase 3, tumor necrosis factor receptor 
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superfamily, and Bcl2) were markedly up- and downregulated, respectively. These results 
indicate that DHEA regulates cell growth or death, possibly resulting in decreased 
adiposity. However, we failed to find evidence of increased apoptosis in adipose tissue and 
cultured adipocytes after DHEA treatment.  
2. Materials and methods 
Materials. [-32P]ATP was purchased from Amersham (Aylesbury, Buckinghamshire, UK). 
[1,2-3H]2-deoxyglucose ([3H]2-DOG) was purchased from DuPont-NEN (Boston, MA). Anti-
phosphotyrosine (PY) antibody was purchased from Transduction Laboratory (Lexington, 
KY). Anti-PKC, anti-Akt and anti-PDK1 antibodies were purchased from Santa Cruz 
Biotechnology (Santa Cruz, CA). DHEA was purchased from Sigma (St. Louis, MO). All 
other chemicals were of reagent grade. 
Adipocyte experiments. Males Wistar rats weighing 150-200 g were fed ad libitum and killed 
by decapitation. Isolated adipocytes were obtained by collagenase digestion of rat 
epididymal fat pads in Krebs-Ringer phosphate (KRP) buffer (pH 7.4) containing 127 mM 
NaCl, 12.3 mM NaH2PO4, 5.1 mM KCl, 1.3 mM MgSO4, 1.4 mM CaCl2, 3% bovine serum 
albumin (BSA), and 2.5 mM glucose (28). Animal care and use were approved by the 
Committee for Animal Care and Use in Gifu University Graduate School of Medicine.  
Transfection study. Plasmids for expression of wt-PKC (M246)/PKC (K281W mutant) 
(kindly supplied by Dr. Shigeo Ohno, Yokohama City University School of Medicine, 
Japan), wt-PDK1/PDK1 (K110N) and wt-Akt/Akt (T308A) (kindly supplied by Dr. 
Robert V. Farese, University of South Florida College of Medicine, USA) were constructed in 
vector SRD, pCDNA3 and pCIS, respectively. Adipocytes (50% vol/vol) were transfected by 
the electroporation method (5 g DNA/cuvette) as described by Quon et al in the presence 
of SRD, pCDNA3 or pCIS eukariocytic expression vector clone, or SRD-, pCDNA3- or pCIS-
containing cDNA encoding wtPKC/∆PKC, wtPDK-1/∆PDK-1 or wtAkt/∆Akt (29). 
Transfected adipocytes were incubated at 37℃ overnight (5% CO2) in Dulbecco’s 
Phosphate-Buffered Saline containing 20 g/ml ampicilin. After overnight incubation, each 
protein content was identified by an enhanced chemiluminescence Western blotting 
detection system according to the manufacturer’s protocol. To ensure equal loading of 
proteins, membrane were stripped and restained with antibodies against -actin. 
PI 3-kinase activity. Isolated rat adipocytes were preincubated with KRP buffer for 30 min. 
The samples were treated with 1 M DHEA at 1 min and 10 min, and were lyzed 
immediately in lysis buffer [20 mM Tris/HCl, pH 7.5, 140 mM NaCl, 20 M 
phenylmethylsulfonyl fluoride (PMSF), 0.5 mM Na3VO4, 1 mM ethylene glycol bis (-
aminoethylether)-N,N,N,N-tetraacetic acid (EGTA), 10% Glycerol, 1% Nonidet P-40, and 10 
g/ml aprotinin]. The lysates were centrifuged at 15,000  g for 10 min at 4℃. Five g of 
anti-PY antibody was added to 500 g of the above resultant supernatant and incubated at 
4℃ overnight. After addition of protein A sepharose for 2 h, the immunoprecipitates were 
washed twice with washing buffer A [20 mM Tris/HCl, pH 7.5, 140 mM NaCl, 1 mM 
dithiothreitol (DTT), and 1% Nonidet P-40], once with LiCl solution (100 mM Tris/HCl, pH 
7.5, 0.5 M LiCl, and 1 mM DTT), and twice with buffer B (10 mM Tris/HCl, pH 7.5, 100 mM 
NaCl, and 1 mM DTT). The PI 3-kinase reaction was started by the addition of a 40 l 
solution containing 20 mM Tris/HCl, pH 7.4, 10 Ci [-32P]ATP, 250 M ATP, 10 mM MgCl2, 
5 mM EGTA, and 20 l (1 mg/ml) of sonicated phosphatidylinositol. After a 10 min 
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incubation at 30℃, the reaction was terminated by the addition of 500 l 1 N HCl. Then, in 
succession, 500 l of CHCl3/methanol (2:1, vol/vol) was added to the samples, which were 
then centrifuged. The extracts were washed with 500 l of CHCl3/methanol/1 N HCl (4:2:3, 
vol/vol), then dried and resuspended in CHCl3. The samples were spotted onto silica gel 60 
thin-layer chromatography (TLC) plates (Merck, Darmstadt, Germany), and visualized by 
autoradiography (X-OMAT film, Eastman Kodak, Rochester, NY) (30). These results were 
then scanned and analyzed with a laser densitometer (UltroScan XL, Pharmacia LKB 
Biotechnology, Tokyo).  
Glucose uptake study Isolated rat adipocytes were incubated with KRP buffer for 30 min, 
followed by treatment with 1 M DHEA or 10 nM insulin for 30 min. Uptake of [3H]2-DOG 
was measured over a 1 min period after treatment with 1 M DHEA or 10 nM insulin. When 
overexpressed rat adipocytes were treated with 1 M DHEA for 30 min, uptake of [3H]2-
DOG was measured over a 1 min period after treatment with 1 M DHEA for 30 min. In 
another experiment when overexpressed rat adipocytes were incubated with or without 1 
M wortmannin for 10 min, followed by treatment with 1 M DHEA for 30 min, uptake of 
[3H]2-DOG was measured over a 1 min period after treatment with 1 M DHEA for 30 min. 
PKC studies Wt-PKC-transfected adipocytes were treated with 1 M DHEA for 10 min, 
respectively, following pretreatment with or without 1 M wortmannin, and were 
terminated by the addition of ice-cold buffer C (20 mM Tris/HCl, pH 7.5, 0.25 M sucrose, 1.2 
mM EGTA, 0.1 mM PMSF, 20 g/ml leupeptin, 20 mM 2-mercaptoethanol, and 10 g/ml 
aprotinin). Each sample was sonicated in buffer C. The homogenates were centrifuged for 60 
min at 105,000  g to separate the cytosol and membrane fractions. After the membranes 
were resuspended in lysis buffer (20 mM Tris/HCl, pH 7.5, 0.25 M sucrose, 20 g/ml 
leupeptin, 20 mM 2-mercaptoethanol, 5 mM EGTA, 0.1 mM PMSF, 2 mM 
ethylenediaminetetraacetic acid, and 1% Triton X-100) for 30 min at 4℃, they were 
sonicated, and then centrifuged for 60 min at 105,000  g to obtain solubilized membrane 
fractions. They were then resuspended in Laemmli sample buffer and boiled for 2 min at 
100℃. Thirty g of each sample was subjected to sodium dodecyl sulfate-polyacrylamide gel 
electrophoresis, transferred to a nitrocellulose membrane, and subjected to Western analysis 
with anti-PKC antibody as described above. These results were then scanned and analyzed 
with a laser densitometer.  
Animal study 
Male Long-Evans Tokushima Otsula (LETO) rats and Otsuka Long-Evans Tokushima 
Fatty (OLETF) rats were obtained from Otsuka Pharmaceutical Co., Ltd. Animals were fed 
CE2 powder ad libitum, and treated with (DHEA group) or without (control group) 0.4% 
DHEA for 52 weeks. They were housed in a specific pathogen-free facility with a 12-h 
light/12-h dark cycle. All procedures for animal care were carried out in accordance with 
protocols approved by the University of Gifu’s Institutional Animal Care Committee. To 
compare the effects of DHEA and testosterone on adiposity, male Wistar rats were fed 
with (control) or without 0.4% DHEA- or 0.4% testosterone-containing food for 4 weeks. 
Body weight, fat weight, and serum levels of glucose, IRI, DHEA-S, and testosterone were 
measured.  
Statistics 
Experimental results were calculated as means ± standard errors. Statistical comparisons 
were performed by ANOVA. Significance was defined as P < 0.05. 
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3. Results 
Overexpression of wild type- and kinase inactive type-PKCPDK1/Akt.  
DHEA stimulated both PI 3-kinase activation and DG production as previously described 
(5). We examined whether DHEA activates PKC, which is thought to be a downstream of 
PI 3-kinase. When isolated adipocytes of LETO rats (control) were treated with or without 
(control: 0 min) 1 µM DHEA for 5 , 10 and 20 min, cytosolic PKC immunoreactivities 
gradually decreased and membrane-associated PKC immunoreactivity were inversely 
increased as previously described (10). Moreover we examined precise mechanism of DHEA 
action in adipocytes. Although each DNA was transfected to rat adipocytes transiently, 
these protein contents were significantly overexpressed in rat adipocytes after overnight 
incubation. Each protein content was identified by an enhanced chemiluminescence 
Western blotting detection system. Each wild type- and kinase inactive type-
PKC/PDK1/Akt-transfected cells exhibited a 2 to 3 fold increase in immunoreactive signal 
of 2-3 fold, compared with nontransfected cells (Fig. 1). 
DHEA-induced 2-DOG uptake.  
First, we examined DHEA-induced 2-DOG uptake in rat adipocytes. DNA, using the 
electroporation system was transfected into adipocytes. DHEA-induced 2-DOG uptake in 
wt-PDK1- and wt-PKC-transfected adipocytes significantly increased to 250±30% and 
280±50%, respectively, compared with the control cells and vector alone-transfected cells 
(Fig. 2). However, wt-Akt-transfected adipocytes had no significant influence on DHEA-
induced 2-DOG uptake in this system, when compared with the control cells and vector 
alone-transfected cells (Fig. 2).  
Second, we also examined the effect of wortmannin pretreatment on DHEA-induced 2-DOG 
uptake. DHEA-induced 2-DOG uptake after pretreatment with 1 M wortmannin for 30 min 
was significantly reduced in wt-PDK1-transfected adipocytes. Similarly, DHEA-induced 2-
DOG uptake after pretreatment with wortmannin for 30 min was significantly reduced in 
wt-PKC-transfected adipocytes (Fig. 2). 
DHEA-stimulated PKC translocation with or without wortmannin pretreatment.  
DHEA-induced membrane-associated PKC immunoreactivity for 20 min in PKC-
transfected cells was greater than that of control cells and tranfected cell without DHEA 
stimualtion. (Fig. 3, lanes 1 and 2). The DHEA-stimulated PKC translocation in PKC-
transfected cells significantly increased to 3-fold greater than the control (Fig. 3, lane 3). 
Pretreatment with wortmannin for 15 min completely suppressed DHEA-stimulated PKC 
translocation from the cytosol to the membrane in PKC-transfected cells (Fig. 3, lane 4). 
These results indicate that DHEA-induced PKC translocation is provoked via a PI 3-kinase 
dependent pathway. 
Effect of DHEA treatment in vivo on insulin-induced glucose uptake in adipocytes of 
OLETF/LETO rats 
We selected a type 2 diabetes animal model, the OLETF rat, and examined the effect of “in 
vivo” DHEA treatment on insulin-, TPA- or DHEA-induced [3H]2-DOG uptake. At 10 wk of 
age, 10 nM insulin-induced [3H]2-DOG uptake in adipocytes of OLETF rat decreased by 45% 
when compared to LETO rat (control). In the 2 weeks treatment with 0.4% DHEA in vivo, 
there were no significant differences in body weight or plasma insulin level but there was a 
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Fig. 1. Overexpression of PDK1, PKC and Akt in rat adipocytes. Isolated rat adipocytes 
were prepared as described in “Materials and Methods”. Adipocytes (50%) were transfected 
by the electroporation method (5 g/cuvette) in the presence or absence (control) of 
eucariocytes expression vector-containing wild and kinase-inactive (KN) cDNA encoding 
PDK-1, Akt and PKC. Transfected adipocytes were incubated at 37°C overnight in 
Dulbeco’s modified buffer. Each protein was identified by ECL western blotting system as 
shown in “Materials and Methods”. Equal loading of protein was confirmed by stripping 
the membrane and staining with anti--actin antibody. Transfection with wild type and 
kinase-negative type (KN) PDK1/PKC/Akt significantly increased immunoreactive 
PDK1/PKC/Akt 2-3 fold compared with nontransfected cells, respectively. Statistical 
significance was determined by Fishers PLSD test. 
significant difference in plasma glucose of OLETF rats as shown in Table 1. After “in vivo” 
treatment with DHEA, insulin-induced glucose uptakes were significantly increased by 50-
100% when compared to untreated OLETF and LETO rats, but not in DHEA- induced 
glucose uptake. TPA-induced glucose uptake was also significantly increased compared to 
untreated OLETF and LETO rats as previously described (5). These results suggested that 
DHEA markedly increased glucose transport activity in not only LETO rats, but also in 
OLETF rats. 
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b) 
Fig. 2. DHEA-induced 2-DOG uptake in transfected adipocytes. a) Isolated adipocytes 
obtained by the electroporation system were stimulated with 1 M DHEA for 30 min. 
Uptake of [3H]2-DOG was measured as shown in “Materials and Methods”. DHEA-induced 
2-DOG uptake in wt-PDK1- and wt-PKC-transfected adipocytes significantly increased to 
250±30% and 280±50%, respectively, compared with the control cells and vector alone-
transfected cells. b) Isolated adipocytes obtained by above procedure were pretreated with 1 
M wortmannin for 30 min, and then stimulated with 1 M DHEA. DHEA-induced 2-DOG 
uptake after pretreatment with wortmannin for 30 min was significantly reduced in wt-
PDK1-transfected and wt-PKC-transfected adipocytes. The data are plotted as mean ± SE of 
three separate experiments. **, P  0.01, vs. control by Fisher’s PLSD test. 
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Fig. 3. DHEA-stimulated membrane-associated PKC immunoreactivity with or without 
wortmannin pretreatment. Adipocytes were transfected wt-PKC DNA using an 
electroporation system. Membrane-associated PKC immunoreactivity was examined by 
Western blotting as shown in “Materials and methods”. DHEA-induced membrane-
associated PKC immunoreactivity in PKC-transfected cells significantly increased to about 
3-fold over the control (lane 3). Pretreatment with wortmannin for 30 min completely 
suppressed DHEA-stimulated PKC immunoreactivity in PKC-transfected cells (lane 4). 
The result is representative one of three separate experiments. 
 
Specimen 
LETO OLETF 
Control DHEA Control DHEA 
Epididymal fat 
(g) 
10.9 ± 1.4 5.5 ± 1.7** 16.6 ± 1.2 11.2 ± 2.1** 
Glucose 
(mg/mL) 
140 ± 1 132 ± 2 184 ± 4 168 ± 3 * 
TG (mg/mL) 101 ± 14 53 ± 2 * 544 ± 42 171 ± 54 ** 
T.Chol (mg/mL) 121 ± 5 139 ± 2 226 ± 7 191 ± 7 
FFA (mEq/L) 645 ± 115 490 ± 16 1225 ± 96 854 ± 214 * 
AST (IU/L) 207 ± 10 331 ± 35 * 202 ± 49 150 ± 21 * 
ALT (IU/L) 75 ± 11 118 ± 9 141 ± 4 101 ± 34 * 
IRI (ng/mL) 1.8 ± 0.4 2.4 ± 0.3 2.4 ± 1 2.7 ± 0.4 
Data are expressed as mean ± SE (N = 6).  
*P < 0.05, **P < 0.01 vs control. 
Table 1. Effect of DHEA Administration on Epididymal Fat Weight and Laboratory Data in 
LETO and OLETF Rats 
Effect of DHEA treatment in vivo on insulin-induced phosphatidylinositol (PI) 3-kinase 
and PKCz activations in OLETF/LETO rats 
Moreover, in order to clarify the effect of DHEA treatment in vivo on PI 3-kinase, which 
binds to tyrosine phosphorylated insulin receptor substrate-1 (IRS-1) via SH2 domain of PI 
3-kinase, downstream of the insulin signaling pathway, we examined whether DHEA 
treatment improves PI 3-kinase activity in adipocytes of OLETF/LETO rats. When  
 
www.intechopen.com
Effect of Dehydroepiandrosterone on Insulin Sensitivity 
and Adipocyte Growth in Otsuka Long-Evans Tokushima-Fatty Rats 
 
135 
LETO OLETF
IInsulin
DHEA
- - -
--
-
- -
+ +
+ +
+ +
+ +
Control DHEA
0
100
200
300
*
*
LETO
Control DHEA
0
100
200
300
OLETF
*
#
PI3- P ・・
 
Fig. 4. Effect of in vivo treatment with DHEA on insulin-induced PI 3-kinase activation in 
adipocytes of OLETF/LETO rats. After treatment with 0.4% DHEA in vivo for 2 wk, 
isolated adipocytes were obtained from epididymal fat pads in OLETF rats. Isolated 
adipocytes were incubated with or without ( control: 0 min) 10 nM insulin for 10 min, 
homogenized, and immunoprecipitated with phosphotyrosine antibody. Each PI 3-kinase 
activity was measured as shown in “Materials and methods”. Densitometric data are plotted 
as the mean ± SE of four separate experiments. *P < 0.01 by ANOVA with Fisher’s PLSD. 
adipocytes were incubated with 10 nM insulin, enzyme activity after immunoprecipitation 
with antiphosphotyrosine antibody apparently increased for 5 and 10 min in control LETO 
rats. PI-3kinase activity of OLETF rat was decreased and insulin-stimulated PI-3kinase 
activity also decreased, compared with those in LETO rats (Fig. 4). In vivo treatment with 
DHEA increased membrane-associated PKCimmunoreactivities, especially in OLETF rat 
as shown in Fig. 5. These results suggest that in vivo treatment with DHEA for 2 weeks 
increases PI 3-kinase/atypicalPKC signaling and finally ameliorate blood glucose level as 
shown in Table 1. 
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Fig. 5. Effect of in vivo treatment with DHEA on insulin-induced PKCtranslocations in 
adipocytes of OLETF/LETO rats. After treatment with 0.4% DHEA in vivo for 2 wk, 
isolated adipocytes were obtained from epididymal fat pads in OLETF rats. Isolated 
adipocytes were stimulated with or without (control) 10 nM insulin for 10, 20 min. Cells 
were homogenized and centrifuged to obtain cytosol and membrane fraction. Membrane-
associated protein (40 µg) was subjected to SDS-PAGE, transferred to the nitrocellulose 
membrane, and immunoblotted with PKCantibodies using ECL system. The result is 
representative one of three separate experiments. 
Effect of DHEA administration on body weight, food consumption, and laboratory Data 
in LETO and OLETF rats 
DHEA administration reduced body weight of both LETO and OLETF rats over a period of 
44 weeks; however, a significant decrease in food consumption was observed only in the 
first 2 weeks. This indicated that DHEA-induced reduction of body weight could not be 
attributed to the change in food intake (Fig. 6). As shown in Table 1, DHEA administration 
significantly reduced epididymal fat weight in LETO and OLETF and plasma glucose level 
in OLETF rats. Serum triglyceride and free fatty acid levels were also diminished by DHEA 
administration.  
Effects of DHEA and testosterone on body weight and fat weight 
Treatment with both 0.4% DHEA and 0.4% testosterone resulted in reduction of body 
weight and epididymal fat, intestinal fat, and perirenal fat weights (Fig. 7A, B). Animals 
were treated for 4 weeks to avoid the effect of decreased food intake. Because rodents lack 
17ǂ-hydroxylase (CYP17A1) in their adrenal glands, they produce little or no DHEA. Hence, 
DHEA-S was not detected in control serum, whereas elevated DHEA-S levels were observed 
in both DHEA-treated and testosterone-treated rats (Fig. 7C). Treatment with DHEA 
resulted in less elevated testosterone levels than treatment with testosterone (Fig. 7D). No 
differences were observed in serum levels of glucose, triglyceride, free fatty acid, AST, ALT, 
and IRI levels among these animals (data not shown).  
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Fig. 6. Effects of DHEA administration on body weight in LETO and OLETF rats  
Both LETO and OLETF rats were treated with or without (Control) 0.4% DHEA-containing 
food. Effects of this treatment on body weight in LETO (A) and OLETF (B) are shown. 
Closed square: Control, Open circle: DHEA, *: P < 0.05, vs Control, +: P < 0.01, vs Control, N 
= 10. 
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Fig. 7. Effects of DHEA and testosterone administration on body weight, fat weight, and 
serum concentration of DHEA-S and testosterone  
Wistar rats were housed with or without 0.4% DHEA- or 0.4% testosterone-containing food 
for 4 weeks. DHEA and testosterone administration produced equal and significant 
decrease in body weight (A), epididymal (black bar), intestinal (white), and perirenal (gray) 
fat weight. *: P < 0.05 vs each control, N = 8. Testosterone (Testo) administration raised 
serum DHEA-S level (C), while DHEA administration significantly elevated serum 
testosterone level (D). *: P < 0.05 vs control, N = 6. 
4. Discussion 
We have previously reported that DHEA improves insulin resistance via activation of PI 3-
kinase/atypical PKC signaling (5). However, more precise mechanism still remains unclear 
concerning about downstream signaling of PI 3-kinase and in vivo effect of DHEA on 
human male adults. Therefore, we have shown in vivo administration of DHEA stimulates 
glucose uptake via activation of PI3-kinase/atypiacal in OLETF rats and improves insulin 
resistance in human male adults. It has been reported that insulin receptor-mediated 
tyrosine phosphorylation of insulin receptor substrate 1 stimulates PI 3-kinase (31). It is 
believed that PI 3-kinase plays an important role in the insulin-stimulated glucose transport 
system (32). It has been reported that PI 3-kinase mediated aPKC activation is essential in 
insulin-induced glucose transporter 4 translocation and glucose uptake (33). The current 
results demonstrate that PDK1 is necessary for phosphorylation and activation of aPKC (34), 
www.intechopen.com
Effect of Dehydroepiandrosterone on Insulin Sensitivity 
and Adipocyte Growth in Otsuka Long-Evans Tokushima-Fatty Rats 
 
139 
and aPKC may provoke glucose transporter translocation to the membrane of insulin 
sensitive tissues (35). Our previous studies show that DHEA may directly or indirectly 
activate PI 3-kinase without an increase in tyrosine phosphorylation of IRS-1 (36) and 
subsequent activation of PKC (13). Although DOG uptake by DHEA stimulation 
significantly increased, it appears to be more than the 150% increases in cultured adipocytes 
from an unstimulated level, as shown in Fig. 2. In this study, we hypothesize that 
overexpressions of PKC and PDK1 may markedly cause DOG uptake. As a result, DHEA-
induced DOG uptake increased 250 and 280% in wt-PDK1- and wt-PKC-transfected 
adipocytes, respectively, when compared with the control and vector-transfected cells, as 
shown in Fig. 2. DHEA-induce glucose uptake was stimulated by activation of PI-3 kinase 
and subsequent stimulation of PDK1/atypical PKC by PIP2/PIP3 production as already 
shown (5), and partially mimics insulin-induced activation of glucose uptake.  
Although we acknowledge that PDK1 can phosphorylate Akt kinase (known as protein 
kinase B), DHEA-induced DOG uptake did not increase in wt-Akt-transfected adipocytes 
(Fig. 2). Moreover, Kotani et al stated that Akt kinase was not associated with insulin-
induced glucose uptake in 3T3-L1 adipocytes (37). Further work will be needed to focus on 
the elucidation of the function of Akt kinase.  
In addition, we investigated the effect of wortmannin, a PI 3-kinase inhibitor, on glucose 
uptake in wt-PKC-transfected adipocytes. When treated with DHEA, PKC significantly 
increased in the membrane fractions as indicated in Fig. 3. (lane 3). However, pretreatment 
with wortmannin for 30 min significantly suppressed DHEA-induced PKC translocation to 
the membrane (Fig. 3, lane 4). We also investigated the effect of wortmannin on DHEA-
induced PI 3-kinase and PKC activity. After pretreatment with wortmannin, DHEA-
induced PI 3-kinase and PKC activations were inhibited completely as previously 
described (10). These results indicate that acute DHEA stimulation may potentiate DOG 
uptake via a PI 3-kinase-PDK1-PKC pathway and subsequent glucose transporter 
translocation.  
Nakashima et al. reported that insulin-stimulated DOG uptake increased by incubating cells 
with DHEA (38). We also revealed that DHEA could enhance insulin-induced DOG uptake 
via activation of PI 3-kinase-PKC signaling in DHEA-treated (for 2 weeks) OLETF (Otsuka 
Long-Evans Tokushima Fatty) rat in vivo, when compared with untreated control rats (5). 
Although the precise mechanism is unknown, the preferential activation of PI 3-kinase and 
redistribution of PKC by chronic DHEA treatment may appear to result in enhancement of 
insulin sensitivity in OLETF rats and human male adults. On the other hand, DHEA 
converts into estrogenic and androgenic metabolites, such as 17-estradiol, 5-androstene-
3,17-diol, testosterone and 4-androstene-3,17-dione (39). Investigators need to examine 
whether DHEA-metabolites affect DOG uptake, although in vitro examinations indicated 
androstenedione and estradiol did not stimulate DOG uptake in native rat adipocytes as 
previously reported (5). Finally, 4-hydroxy-androstenedione, an aromatase inhibitor, may be 
useful in evaluating the effect of DHEA. 
In this study, DHEA treatment for 2 wk in genetically obese OLETF rats reduced the weight 
of subcutaneous and visceral adipose tissues, but not total body weight. Although a small 
effect could also be observed also in control rats, DHEA decreased a broad range of adipose 
in fatty ones. We also revealed that DHEA treatment significantly reduced plasma leptin 
level as previously reported (11). Leptin is thought to correlate with the amount of stored 
body. Therefore, DHEA-induced reduction in adipose tissue mass might contribute to the 
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decrease in plasma leptin concentration. Moreover, we found that DHEA treatment 
prevented the elevation of PPAR expression in adipose tissue from OLETF rats (11). The 
present study could not ascertain whether the expression of PPAR in adipose tissue is 
genetically determined or not. However, considering the fact that an increased amount of 
PPAR expression in obese human adipose tissue, which is proportional to BMI, can be 
reduced by a low calorie diet (40), our result seems to suggest an acquired origin. We 
questioned whether these effects of DHEA on adipose tissue are direct or not. Interestingly, 
DHEA-S cannot stimulate peroxisomal gene induction in the liver of PPAR knockout mice, 
suggesting that some of the DHEA or DHEA-S actions are mediated via the PPAR family 
(41). These results are supposed to be biologically significant, because Pro 12 Ala 
substitution in the human PPAR gene, which exhibits 30-45% less transactivation capacity, 
leads to prevention of obesity and insulin resistance (24). Our recent preliminary study 
revealed that the effect of DHEA on PPAR was enhanced in adipocytes with 
overexpression of PKC (11). We previously reported that DHEA activates 
phosphatidylinositol 3-kinase (PI 3-kinase) and atypical PKC (10). In addition, TNF-, 
another PPAR reducing agonist, also activated atypical PKC (42).  
Based on the above results, DHEA may improve insulin resistance via activation of glucose 
transport and downregulations of adiposity through the activation of PI 3-kinase/PKC 
signaling and the reduction of PPAR and, finally, DHEA may contribute to the 
amelioration of insulin sensitivity in diabetic model animals. These results suggest that 
DHEA may be useful for clinical application for insulin resistant state such as diabetes, 
obesity, hyperlipidmia and hypertension, recently called as metabolic syndrome in the 
future time. 
Since the presentation by Coleman and colleagues suggested that DHEA administration 
prevented diabetes in db/db mice, numerous studies have been published (20). Our 
previous study revealed that although treatment with DHEA fails to decrease blood glucose 
in Goto-Kakizaki rats, an animal model of lean type 2 diabetes, it significantly reduces blood 
glucose in OLETF rats (5). Therefore, we speculated that DHEA administration might 
improve obesity-associated diabetes in association with preventing obesity-induced insulin 
resistance. We found that treatment with DHEA for 2 weeks reduced fat mass and that 
DHEA directly suppressed mRNA levels of PPARǄ in isolated adipocytes (11). Since 
suppression of PPARǄ activity leads to reduced adiposity in PPARǄ-deficient mice (43) and 
Pro12Ala polymorphism in humans (44), our result could explain the weight-reducing effect 
of DHEA. On the other hand, our microarray experiment revealed that genes regulating cell 
proliferation were more profoundly influenced by DHEA administration than those 
regulating energy homeostasis in adipose tissue. Hence, we examined the effect of DHEA on 
cell proliferation in adipose tissue.  
In this study, we demonstrated that we compared the effects of DHEA and testosterone 
administration. Long-term DHEA administration decreased body weight of both LETO and 
OLETF rats (Fig. 6). Although several studies indicated that the anti-obesity effect of DHEA 
was associated with decreased food intake, no difference was observed in food consumption 
except for that in the first 2 weeks. It was suggested that DHEA-induced central 
neurotransmitter changes suppress the appetite; however, these changes may not persist 
longer than 3 weeks (45).  
Epidemiological studies suggest that high plasma DHEA-S level is associated with longevity 
(46, 47), whereas, to our knowledge, our study is the first to provide evidence of the anti-
aging effect of DHEA. Both DHEA and testosterone led to decreased visceral fat weight 
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when administered for 4 weeks. These results imply that treatment with these hormones 
acts similarly on adipose tissue. Moreover, dot blot analysis revealed that both testosterone 
and DHEA administration yielded identical results. In addition, our results suggest that 
DHEA administration could substitute for testosterone replacement; however, because 
DHEA is known to act as a neurosteroid and other unique actions of DHEA are known, 
further study is necessary to understand the difference between these hormones. 
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